PMID- 36921501 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20230601 IS - 1879-1379 (Electronic) IS - 0022-3956 (Linking) VI - 161 DP - 2023 May TI - Assessment of patient life engagement in major depressive disorder using items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR). PG - 132-139 LID - S0022-3956(23)00067-5 [pii] LID - 10.1016/j.jpsychires.2023.02.008 [doi] AB - BACKGROUND: Patient-reported outcomes can measure domains that are personally meaningful, such as life engagement, which reflects motivation, pleasure, and well-being. This study explored whether certain items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR) can capture patient life engagement in major depressive disorder (MDD). METHODS: IDS-SR life engagement items were identified by a) a panel of expert psychiatrists (n = 4), b) patient interviews (n = 20), and c) a principal component analysis (PCA) to explore clustering of items. Psychometric analyses were performed on potential subscales, and a minimal clinically important difference (MCID) was estimated by anchor- and distribution-based methods. IDS-SR data were obtained from three randomized controlled trials of adjunctive brexpiprazole in MDD. RESULTS: Expert psychiatrists selected 10 items by consensus from the IDS-SR that might capture patient life engagement (Cronbach's alpha, 0.82; item-total correlations, 0.36-0.58). Patient interviews identified 13 items as moderately to very relevant to life engagement (Cronbach's alpha, 0.85; item-total correlations, 0.35-0.61). The PCA revealed a cluster that included all 10 items selected by psychiatrists and 11 items identified by patients. Expert psychiatrists intentionally distinguished life engagement and core depressive symptoms, although patient insights and the PCA indicated that these aspects of MDD are strongly linked. The 10-item IDS-SR life engagement subscale had an MCID of 3-5 points. CONCLUSIONS: Different approaches consistently identified a subset of 10 IDS-SR items that can measure life engagement in MDD, which may be suitable to group into an IDS-SR life engagement subscale. CI - Copyright (c) 2023. Published by Elsevier Ltd. FAU - Thase, Michael E AU - Thase ME AD - Perelman School of Medicine, University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA. Electronic address: thase@pennmedicine.upenn.edu. FAU - Ismail, Zahinoor AU - Ismail Z AD - Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada. FAU - Meehan, Stine R AU - Meehan SR AD - H. Lundbeck A/S, Valby, Copenhagen, Denmark. FAU - Weiss, Catherine AU - Weiss C AD - Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA. FAU - Regnier, Stephane Alexandre AU - Regnier SA AD - H. Lundbeck A/S, Valby, Copenhagen, Denmark. FAU - Larsen, Klaus Groes AU - Larsen KG AD - H. Lundbeck A/S, Valby, Copenhagen, Denmark. FAU - McIntyre, Roger S AU - McIntyre RS AD - Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230206 PL - England TA - J Psychiatr Res JT - Journal of psychiatric research JID - 0376331 SB - IM MH - Humans MH - *Depressive Disorder, Major/diagnosis MH - Self Report MH - Psychometrics MH - Principal Component Analysis MH - Pleasure OTO - NOTNLM OT - Antidepressant OT - Life engagement OT - Major depressive disorder OT - Patient-reported outcome COIS- Declaration of competing interest Michael E. Thase has served as an advisor/consultant for AbbVie (Allergan), Acadia, Alkermes, Axsome, Clexio, H. Lundbeck A/S, Johnson & Johnson (Janssen), Merck & Company Inc, Novartis, Otsuka, Pfizer, Sage Pharmaceuticals, Sunovion Pharmaceuticals Inc, and Takeda; he has received grant support from Acadia, Axsome, Clexio, Janssen, National Institute of Mental Health, Otsuka, Patient-Centered Outcomes Research Institute (PCORI), and Takeda; and royalties from American Psychiatric Foundation, Guilford Publications, Herald House, Wolters Kluwer, and WW Norton & Company Inc; and his spouse is employed by Peloton Advantage, which does business with most major pharmaceutical companies. Zahinoor Ismail has received grant support from CIHR, NIH, Brain Canada, and Weston Foundation, and has served as a consultant for Janssen, Lundbeck, and Otsuka. Additionally, his institution has received funds on his behalf from Acadia, Biogen, and Roche. Stine R. Meehan, Stephane Alexandre Regnier, and Klaus Groes Larsen are full-time employees of H. Lundbeck A/S. Catherine Weiss was a full-time employee of Otsuka Pharmaceutical Development & Commercialization Inc. at the time that this work was conducted. Roger S. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC); and speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, AbbVie, and ATAI Life Sciences. He is a CEO of Braxia Scientific Corp. EDAT- 2023/03/16 06:00 MHDA- 2023/05/01 06:42 CRDT- 2023/03/15 19:13 PHST- 2022/09/01 00:00 [received] PHST- 2023/01/24 00:00 [revised] PHST- 2023/02/05 00:00 [accepted] PHST- 2023/05/01 06:42 [medline] PHST- 2023/03/16 06:00 [pubmed] PHST- 2023/03/15 19:13 [entrez] AID - S0022-3956(23)00067-5 [pii] AID - 10.1016/j.jpsychires.2023.02.008 [doi] PST - ppublish SO - J Psychiatr Res. 2023 May;161:132-139. doi: 10.1016/j.jpsychires.2023.02.008. Epub 2023 Feb 6.